HYDROCHLOROTHIAZIDE W/ RESERPINE Drug Patent Profile

Which patents cover Hydrochlorothiazide W/ Reserpine, and when can generic versions of Hydrochlorothiazide W/ Reserpine launch?

Hydrochlorothiazide W/ Reserpine is a drug marketed by Ivax Sub Teva Pharms, Pharmeral, Roxane, and Watson Labs. and is included in fourteen NDAs.

The generic ingredient in HYDROCHLOROTHIAZIDE W/ RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.

Summary for HYDROCHLOROTHIAZIDE W/ RESERPINE

US Patents:	0
Applicants:	4
NDAs:	14

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W/ RESERPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Sub Teva Pharms	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083572-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roxane	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	084603-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ivax Sub Teva Pharms	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083573-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	084467-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	084466-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE	hydralazine hydrochloride; hydrochlorothiazide; reserpine	TABLET;ORAL	083770-001	Approved Prior to Jan 1, 1982		DISCN	No	No